COMMUNIQUÉS West-GlobeNewswire

Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
29/10/2026
Oral presentations to include four-year follow-up data from patients who received a one-time 50 milligram (mg) dose of lonvo-z; insights on new hereditary angioedema (HAE) treatment goals Poster presentations to include [...]
MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide
29/10/2026
SKNY-1's Weight Reduction Without Significant Changes in Food Consumption Suggests a Potential Role for Energy Expenditure, Contrasting With Semaglutide's Initial Food-Intake Suppression and Significant Post-Treatment [...]
Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics
29/10/2026
U.S. FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria; additional Phase 2 studies planned in food allergy and relapsing multiple sclerosis Company expands pipeline through research [...]
Oak Hill Bio to Present at Upcoming Investor Conferences
29/10/2026
CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- OHB Pediatrics Ltd d/b/a Oak Hill Bio, a clinical-stage rare disease therapeutics company, today announced that the company will participate in the following investor [...]
Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026
29/10/2026
Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updates MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company [...]
Immutep Quarterly Activities Report Q1 FY27
29/10/2026
Media Release Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS <1 and the neoadjuvant setting of STS, with preparations for future clinical trials underway [...]
Breckenridge Distillery and University of Denver Athletics Release Limited-Edition Whiskey Celebrating Record 11th NCAA Men’s Hockey Championship
29/10/2026
$100 from every bottle sold will benefit Denver men’s ice hockey scholarships DENVER, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery , an award-winning craft distillery and subsidiary of Tilray Brands, Inc. ( [...]
SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
29/10/2026
JERSEY CITY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that the [...]
MediWound to Report Third Quarter 2026 Financial Results
29/10/2026
MediWound to Report Third Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, November 12 th at 8:30 a.m. Eastern Time YAVNE, Israel, October 29, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a [...]
aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine
29/10/2026
Peer-reviewed publication reinforces efzofitimod’s differentiated profile and potential to advance pulmonary sarcoidosis care. SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the [...]
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
29/10/2026
KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile KT-579 LUMORA Phase 1b trial in lupus patients [...]
Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London
29/10/2026
BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system [...]
Verano Announces Strong Third Quarter 2026 Financial Results Highlighted by $212 Million in Revenue and Year-Over-Year Organic Growth
29/10/2026
Company generates revenue increase of $10 million, or 5%, and highest level of cash flow from operations in four years CHICAGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“ [...]
Ligand Reports Third Quarter 2026 Financial Results
29/10/2026
Third-quarter royalty revenue up 51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.50 1 ; Reaffirms Revenue Guidance Conference call begins at 8: [...]
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
29/10/2026
DEL Technology Integrating C4T’s Cereblon Library Can Rapidly Advance Projects Into Hit-To-Lead Stage WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage [...]
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
29/10/2026
Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease Lecanemab presentations will [...]
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
29/10/2026
DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
29/10/2026
Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14 ZUG, Switzerland, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company [...]
Biosplice Executives to Appear on Health Uncensored with Dr. Drew on Sunday, November 1
29/10/2026
Chief Executive Officer Erich Horsley and Chief Medical Officer Dr. Yusuf Yazici discuss the need for innovation in knee osteoarthritis and the development of lorecivivint, which is now under regulatory review in the [...]

Pages